Drug Trial Radar · NCT01197521
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
923
Actual
Start
Sep 2010
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding. The study will last for 1 year.
Conditions
- Rheumatoid Arthritis
Interventions
fostamatinibDrug
fostamatinib 100 mg twice daily
fostamatinibDrug
fostamatinib 100 mg twice daily/150 mg once daily
placebo, fostamatinibDrug
Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo.Time frame: 24 weeks
- Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo.Time frame: Baseline and 24 weeks
Locations
127 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama
Research Site
Huntsville, Alabama
Research Site
Tuscaloosa, Alabama
Research Site
Tucson, Arizona
Research Site
Huntington Beach, California
Research Site
Long Beach, California
Research Site
Santa Maria, California
Research Site
Santa Monica, California
Research Site
Colorado Springs, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Lewes, Delaware
Research Site
Daytona Beach, Florida
Research Site
Ocala, Florida
Research Site
Atlanta, Georgia
Research Site
Marietta, Georgia
Research Site
Idaho Falls, Idaho
Research Site
Springfield, Illinois
Research Site
Wichita, Kansas
Research Site
Bowling Green, Kentucky
Research Site
Flowood, Mississippi
Research Site
Florissant, Missouri
Research Site
Richmond Heights, Missouri
Research Site
St Louis, Missouri
Research Site
Kalispell, Montana
Research Site
Albuquerque, New Mexico
Research Site
Albany, New York
Research Site
Brooklyn, New York
Research Site
Olean, New York
Research Site
Asheville, North Carolina
Research Site
Greensboro, North Carolina
Research Site
Perrysburg, Ohio
Research Site
Lake Oswego, Oregon
Research Site
Erie, Pennsylvania
Research Site
Waxford, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Hixson, Tennessee
Research Site
Memphis, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Mesquite, Texas
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.